ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 0234

Identifying Optimal Serum Urate Levels to Reduce Gout Flares in Patients Taking Urate Lowering Therapy: A Post-hoc Cohort Analysis of CARES with Consideration of Drop-out
Abstract Number: 0235

Fractures in Patients with Acute CPP Crystal Arthritis versus Matched Comparators in a Large Cohort Study
Abstract Number: 0236

Treatment-emergent Major Adverse Cardiovascular and Thromboembolic Events Were Infrequent During Pegloticase Therapy: Pooled Clinical Trial Findings
Abstract Number: 0237

Oral Urate-Lowering Therapy Use and Efficacy Following Pegloticase Treatment: Findings from a Rheumatology Network Database
Abstract Number: 0238

Adherence to the Gout and Crystal Arthritis Network (G-CAN) Consensus Statements for Gout Nomenclature
Abstract Number: 0239

Incidence and Prevalence of Cardiovascular and Metabolic Diseases Following Gout Diagnosis in the United Kingdom Using the THIN Database
Abstract Number: 0240

Gout: A Gateway to Chronic Opioid Use?
Abstract Number: 0241

Gout Flares During the Initiation and Escalation of Treat-to-Target Urate Lowering Therapy: A Post-hoc Analysis of a Randomized Multicenter Comparative Effectiveness Trial
Abstract Number: 0242

Venous Thromboembolism in Patients with Gout in the US
Abstract Number: 0243

Decreased Incidence of Gout After Kidney Transplant over the Last Decade: An Analysis from a Large Academic Renal Transplant Center
Abstract Number: 0244

Efficacy and Safety of AR882, a Selective Uric Acid Transporter 1 (URAT1) Inhibitor, in Gout Patients with Various Baseline Characteristics Following 12-Week Treatment in Patients
Abstract Number: 0245

Impact of Combined Intervention with Clinical Nurse Specialist in the Management of Cardiovascular Risk in Patients with Gout
Abstract Number: 0246

Safety & Efficacy of SEL-212 in Patients with Gout Refractory to Conventional Treatment: Primary Outcomes from Two Randomized, Double Blind, Placebo-Controlled, Multicenter Phase 3 Studies
Abstract Number: 0247

Risk of Incident Gout Following Exposure to Recombinant Zoster Vaccine in Adults Aged ≥50 Years in the United States
Abstract Number: 0248

In-hospital Treatment, Secondary Prevention, and Mortality After First-ever Acute Myocardial Infarction in Patients with Gout

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].